ABOUT CAMURUS PRODUCTS PIPELINE TECHNOLOGIES INVESTORS MEDIA CONTACT ENGLISH THE CAMURUS SHARE 159.20 SEK -2.33% XSTO 2021-11-26 17:29 MARKET CAP: 8,634 MSEK ABOUT CAMURUS Delivering better treatments Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. More about Camurus PRESS RELEASES 2021-11-11 Camurus announces dosing... 2021-11-04 Camurus’ Interim Report... 2021-10-27 Camurus’ Nomination... 2021-10-13 Camurus appoints Jon U.... Archive FINANCIAL CALENDAR 2022-02-16 Full Year Report 2021 2022-04-06 Annual Report 2021 2022-05-12 Interim Report January-March 2022 2022-07-15 Interim Report January-June 2022 See more EVENTS & PRESENTATIONS 2021-12-16 DNB Nordic Healthcare... See more DEVELOPMENT PIPELINE Transforming treatments for patients with serious and chronic diseases Camurus' clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery. See our pipeline CAM2029 GROWTH HORMONE DISORDERS CAM2038 CHRONIC PAIN CAM2032 PROSTATE CANCER EPISIL® ORAL LIQUID INVESTOR RELATIONS Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us. Investor relations Stable growth and positive development during the third quarter Fredrik Tiberg CEO Statement Q3 2021 TECHNOLOGIES FluidCrystal®- smart and versatile drug delivery Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. Technologies FluidCrystal® INJECTION DEPOT FluidCrystal® TOPICAL BIOADHESIVE FluidCrystal® NANOPARTICLES Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Ideongatan 1A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com ABOUT CAMURUS PRESENTATIONS PIPELINE PRODUCTS TECHNOLOGIES INVESTORS CAREER LEGAL NOTICE PRIVACY CONTACT IR CONTACT By continuing to use the site, you agree to the use of cookies. more information Accept